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Edited by Laszlo NagyAbstract Peroxisome proliferator-activated receptor a
(PPARa) is a nuclear receptor that regulates the expression of
genes associated with lipid metabolism. Recent studies have sug-
gested that the expression of PPARa-dependent ﬁbroblast
growth factor 21 (FGF21) plays important roles in adaptation
to fasting, such as lipolysis and ketogenesis. We found that a
nighttime injection of bezaﬁbrate, a ligand of PPARa, eﬀectively
induced FGF21 expression, whereas a daytime injection did not
aﬀect it. Furthermore, bezaﬁbrate-induced circadian FGF21
expression was abolished in PPARa-deﬁcient mice. These obser-
vations suggest that bezaﬁbrate-induced circadian FGF21
expression is due to circadian variations in the responsiveness
of the PPARa system in the liver.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Peroxisome proliferator-activated receptor a (PPARa) is a
nuclear receptor that regulates the transcription of numerous
genes involved in lipid metabolism and energy homeostasis
[1,2]. Binding of ligands to PPARa leads to obligate heterodi-
merization with 9-cis retinoic acid receptor (RXR) and subse-
quent recruitment of coactivators, resulting in the initiation of
DNA transcription of target genes [1,3]. Recent studies have
revealed that PPARa-dependent ﬁbroblast growth factor 21
(FGF21) plays an important role in adaptation to fasting, such
as adipose lipolysis, hepatic ketogenesis and torpor [4–6]. Fast-
ing remarkably increases hepatic FGF21 mRNA levels due to
PPARa activation via PPAR binding elements in the FGF21
promoter [4]. Phylogenetic and structural analyses have as-
signed FGF21 to the FGF19 subfamily, which comprises
FGF19 (mouse FGF15), FGF21 and FGF23 [7]. These FGFs
are distinguished from other FGFs in that they function in an
endocrine fashion presumably due to having low aﬃnity for
heparin. Notably, FGF21 inﬂux into the brain occurs via the
blood–brain barrier [8].
We recently showed that administering mice with bezaﬁ-
brate, a PPARa ligand, induces time-dependent torpor-like
phenomena [9]. Chronic administration of bezaﬁbrate induces*Corresponding authors. Fax: +81 29 861 9499.
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doi:10.1016/j.febslet.2008.09.046FGF21 expression in the liver and decreases body temperature
during the latter half of the dark period [9]. The PPARa-
FGF21 pathway could be involved in these torpor-like phe-
nomena, because body temperature decreases time-depen-
dently in fasting FGF21 transgenic mice and in fasting mice
infected with an adenovirus expressing FGF21 [4]. However,
the mechanism underlying the time-dependent torpor-like phe-
nomena induced by the PPARa-FGF21 pathway has not been
elucidated. We postulated that FGF21 expression is regulated
by a circadian mechanism in mice administered with bezaﬁ-
brate. Here, we examined the temporal expression proﬁles of
FGF21 in bezaﬁbrate-treated wild-type (WT) and PPARa-
deﬁcient mice.2. Materials and methods
2.1. Animals and manipulation
We crossed PPARa-null mice (129S4SvJae-Pparatm1Gonz/J; The
Jackson Laboratory) with Jcl:ICR mice (Clea Japan Inc.). The result-
ing F1 pups that were heterozygous for the PPARa deletion were fur-
ther mated to generate WT and PPARa KO littermates. Male Jcl:ICR
(Clea Japan Inc.), PPARa KO and littermate WT mice aged 5–8 weeks
were housed under a 12 h light–12 h dark cycle [LD 12:12; lights on at
Zeitgeber time (ZT) 0] and provided with either a normal diet (AIN-
93M, Oriental Yeast, Tokyo, Japan) or the same diet containing
0.5% w/w bezaﬁbrate (Sigma Chemical Co., St. Louis, MO, USA)
for 5 days. A white ﬂuorescent lamp provided light (200–400 lux at
cage level) during the day. To examine the transient eﬀect of bezaﬁ-
brate injection on hepatic gene expression, bezaﬁbrate was adminis-
tered intraperitoneally (i.p.) in a single dose of 100 mg/kg body
weight in 50% dimethyl sulfoxide/saline. Animal experiments and han-
dling were conducted under the permission of our institutional Animal
Care and Use Committee (Permission # 36-07-083).
2.2. Quantitative reverse transcription (RT)-PCR
Total RNA was extracted using guanidinium thiocyanate followed
by RNAiso (Takara Bio Inc., Otsu, Japan) and then digested with
DNase I (Applied Biosystems/Ambion, TX, USA). Single-strand
cDNA was synthesized using the PrimeScript RT reagent kit (Takara
Bio Inc.). Real-time RT-PCR proceeded using the SYBR Premix Ex
Taq II (Takara Bio Inc.) using a LightCycler (Roche Diagnostics,
Mannheim, Germany). The reaction conditions were 95 C for 10 s,
followed by 45 cycles at 95 C for 5 s, at 57 C for 10 s and 72 C
for 10 s. Table 1 shows the sequences of the primer pairs. The amount
of mRNA was corrected relative to that of b-actin.3. Statistics
Data are expressed as means ± S.E.M. Data were statisti-
cally evaluated by applying the two-way and one-way analysisblished by Elsevier B.V. All rights reserved.
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Table 1
Primer sequences for quantitative real-time PCR
Gene Direction Primer sequence
FGF21 Forward ATGGAATGGATGAGATCTAGAGTTGG
Reverse TCTTGGTGGTCATCTGTGTAGAGG
PDK4 Forward CACATGCTCTTCGAACTCTTCAAG
Reverse TGATTGTAAGGTCTTCTTTTCCCAAG
ACOX1 Forward TCGAAGCCAGCGTTACGAG
Reverse ATCTCCGTCTGGGCGTAGG
PPARa Forward TGCAAACTTGGACTTGAACG
Reverse AGGAGGACAGCATCGTGAAG
mPer2 Forward TTCCACTATGTGACAGCGGAGG
Reverse CGTATCCATTCATGTCGGGCTC
Rev-erba Forward CCCTGGACTCCAATAACAACACA
Reverse GCCATTGGAGCTGTCACTGTAG
b-Actin Forward CACACCTTCTACAATGAGCTGC
Reverse CATGATCTGGGTCATCTTTTCA
3640 K. Oishi et al. / FEBS Letters 582 (2008) 3639–3642of variance (ANOVA). We also performed the post-hoc
Welchs t-test and values of P < 0.05 were considered statisti-
cally signiﬁcant.0
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Fig. 1. Temporal mRNA expression proﬁles of FGF21, PDK4,
ACOX1, and circadian clock genes in the livers of bezaﬁbrate-treated
mice. Mice were maintained under an LD 12:12 (lights on at ZT0) and
fed with a diet containing bezaﬁbrate for 5 days. Total RNA was
extracted from livers of control mice (open circles) and of those given
bezaﬁbrate (closed circles), and then mRNA levels were determined by
quantitative RT-PCR. Maximal value for control mice is expressed as
100%. Values are means ± S.E.M. (n = 4–5). Signiﬁcant diﬀerences
compared with value from control mice at each time point are
indicated as *P < 0.05 and **P < 0.01.4. Results
We examined temporal FGF21 mRNA levels and the other
prototypical PPARa target genes pyruvate dehydrogenase ki-
nase 4 (PDK4) and acyl-CoA oxidase 1 (ACOX1) in the livers
of mice administered with bezaﬁbrate for 5 days (Fig. 1). Bez-
aﬁbrate signiﬁcantly induced hepatic expression of these genes.
Furthermore, levels of FGF21 and PDK4 mRNA expression
robustly ﬂuctuated in a circadian manner, while those of
ACOX1 were persistently elevated in the livers of bezaﬁ-
brate-treated mice. The levels of induction of both FGF21
and PDK4 mRNAs were highest at the time of the dark-to-
light transition. Levels of PPARa mRNA ﬂuctuated in a circa-
dian manner in control mice, and were slightly, but not signif-
icantly damped in the mice given bezaﬁbrate. Circadian
expression of the clock genes mPer2 and Rev-erba was signiﬁ-
cantly damped in the bezaﬁbrate-treated mice.
To determine whether the circadian augmentation of FGF21
expression in the bezaﬁbrate-treated mice was due to the circa-
dian changes in responsiveness to bezaﬁbrate, we injected bez-
aﬁbrate at ZT2 and ZT14 (Fig. 2). Injection at ZT14
signiﬁcantly induced FGF21 expression (about 8-fold) in the
mouse liver, although that at ZT2 did not aﬀect FGF21mRNA
levels. Bezaﬁbrate increased PDK4 mRNA expression levels
>20-fold and 10-fold at ZT14 and at ZT2, respectively. These
observations indicated that responsiveness to bezaﬁbrate in the
mouse liver ﬂuctuates in a circadian manner, and that levels in-
crease during the dark phase.
To conﬁrm that PPARa is involved in the bezaﬁbrate-in-
duced circadian expression of FGF21, we examined FGF21
mRNA expression levels in the livers of PPARa-null and bez-
aﬁbrate-treated wild-type mice. Fig. 3 shows that the FGF21
mRNA levels ﬂuctuated between day and night in WT mice gi-
ven bezaﬁbrate. Expression levels of FGF21 mRNA were obvi-ously reduced throughout the day in the livers of bezaﬁbrate-
treated PPARa KO mice. Rhythmic expression of PDK4
mRNA was also obviously damped in the PPARa KO mice.
Therefore, PPARa is involved in the bezaﬁbrate-induced circa-
dian expression of FGF21 mRNA in the mouse liver.5. Discussion
We showed here that bezaﬁbrate induces robust circadian
FGF21 expression in the mouse liver, and that the rhythmic
augmentation of FGF21 expression is PPARa-dependent. Bez-
aﬁbrate-induced 100- to 335-fold increases in PDK4 mRNA
levels in a circadian manner, whereas the basal mRNA levels
ﬂuctuated in the liver as reported [10]. The induction proﬁle
of FGF21 was similar for PDK4 but not for ACOX1, although
both PDK4 and ACOX1 are direct transcription targets of
PPARa, and are involved in fatty acid transport and peroxi-
somal fatty acid oxidation, respectively [2]. These observations
suggest that PPARa regulates the transcription of its target
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Fig. 2. Transient eﬀect of bezaﬁbrate injection on FGF21 expression in
mouse liver. Bezaﬁbrate (100 mg/kg BW) was intraperitoneally injected
into mice at ZT2 (open squares) or ZT14 (closed squares). After 2, 4
and 8 h, mice were decapitated and liver tissues were dissected. Open
and closed circles indicate vehicle injection at ZT2 and ZT14,
respectively. Values at times of injection are expressed as 100% in
each graph and are represented as means ± S.E.M. (n = 3–5). Signif-
icant diﬀerences compared with value at vehicle control are indicated
as *P < 0.05.
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Fig. 3. Circadian FGF21 expression induced by bezaﬁbrate is abol-
ished in PPARa-deﬁcient mice. Both WT and PPARa KO mice were
maintained under an LD 12:12 (lights on at ZT0) and fed with a diet
containing bezaﬁbrate for 5 days. Mice were decapitated at ZT8 (day;
open bars) and ZT20 (night; closed bars), and liver tissues were
dissected. Values at ZT8 of WT mice are expressed as 100% in each
graph and are represented as means ± S.E.M. (n = 3). Signiﬁcant
ﬂuctuations between day and night are indicated as *P < 0.05 in each
genotype.
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ences in the half-life of the mRNAs for these genes. We also
found that nighttime bezaﬁbrate injections signiﬁcantly in-
duced FGF21 expression, whereas morning injections had no
eﬀect, suggesting circadian variations in the responsiveness of
the PPARa system [11]. This might be due in part to circadian
changes in PPARa expression that are directly regulated by
circadian clock components [12].
Circadian clocks exist in most mammalian peripheral tissues,
while the central clock resides in the suprachiasmatic nucleus
of the hypothalamus in the brain. Circadian expression of
mPer2 and Rev-erba, which are core components of the circa-
dian clock, was damped in the livers of bezaﬁbrate-treated
mice in the present study as we have already reported [13].
The circadian expression of several clock (mPer1, mPer2,
Rev-erba) and clock-controlled (PPARa) genes is regulated
by CLOCK/BMAL1-dependent transactivation via the E-box
element. Our ﬁndings suggest that PPARa activation aﬀects
the circadian clock by down-regulating the CLOCK/
BMAL1-dependent circadian transactivation of clock genes,
although the underlying mechanism remains to be elucidated.
Serum levels of FGF21 remain stable throughout the day in
healthy humans [14]. We found here that hepatic FGF21
mRNA levels remained low and essentially constant in mice
fed with a normal diet. These ﬁndings support the notion that
circadian FGF21 expression depends on PPARa activation.On the other hand, neither short-term fasting nor a ketogenic
diet aﬀects serum FGF21 levels in humans [14], unlike those in
mice [4,15]. The physiological role of FGF21 in humans re-
quires further elucidation.
Levels of FGF21 mRNA can be profoundly modulated in
various types of tissues under several conditions [15–19]. Met-
abolic disorders associated with obesity and diabetes induce
FGF21 expression in mouse adipose tissues as well as the liver
[15,17–19]. We examined temporal FGF21 expression in the
livers of mice on a high-fat diet (data not shown). However,
we could not identify circadian FGF21 mRNA augmentation,
although the mRNA levels were signiﬁcantly increased
throughout the day. The expression of FGF21 mRNA induced
by a ketogenic diet is not aﬀected by a PPARa deﬁciency, indi-
cating that FGF21 induction can also be independent of
PPARa [17]. Recent studies have revealed that PPARc is in-
volved in adipose FGF21 expression in vitro [20] and in vivo
[19]. Therefore, FGF21 expression induced by a high-fat diet
might be regulated by PPARc without signiﬁcant rhythmicity.
The response to fasting is abnormal, and both fatty acid oxi-
dation and ketogenesis are defective in PPARa KO mice [21].
Recent studies have demonstrated that PPARa-dependent
FGF21 induction plays an important role in adaptation to
fasting such as ketogenesis in the liver, lipolysis in adipose tis-
sue and torpor [5]. A nocturnal increase in PPARa responsive-
ness might confer an advantage upon nocturnal animals in
3642 K. Oishi et al. / FEBS Letters 582 (2008) 3639–3642terms of the response to fasting. We found that a nighttime
injection of bezaﬁbrate-induced FGF21 expression in noctur-
nal mice whereas a daytime injection did not. These observa-
tions suggest that FGF21 expression is not induced under
normal ad libitum feeding cycles (daytime fasting) but that it
is induced during unusual fasting (nighttime fasting) in mice.
Therefore, the circadian induction of FGF21 expression seems
to be important for the brain to detect unusual metabolic
states. The present ﬁndings have important physiological and
pathophysiological implications for elucidating relationships
between peripheral metabolic status and the central nervous
system (CNS) that regulate the circadian rhythms of body tem-
perature, sleep–wake cycle, and behavior. Although FGF21 is
an important endocrine hormone involved in adaptation to
fasting, whether it directly or indirectly regulates CNS func-
tions via metabolic changes such as ketogenesis remains to
be elucidated.
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